Immunic AG is a young biotech company based in the Munich biotech hub Martinsried that develops pharmaceuticals in the immunology space, in particular for autoimmune diseases or diseases that have an important immunology component in its pathogenesis.
Mission of Immunic AG: Immunic AG is a start-up biotech company focused on the development of immune modulators to block TH
17- and TH
1-mediated immune and autoimmune responses. The final aim is to develop these drug candidates to clinical proof of concept.
Series A financing round extended to EUR 21.7 Million Immunic’s investor base broadened by IBG fund which is managed by bmp Beteiligungsmanagement Expanded funding accelerates further development of IMU-838 and ...Read More
Two executives with deep understanding of the immunology field, and with experience in the IMU-838/IMU-366 development programs add to the Management Board of Immunic AG – experienced biotech CFO is ...Read More
Immunic acquires two promising drug development programs with validated targets known to be relevant in various immune and autoimmune diseases IMU-838: New oral treatment option for Crohn’s disease IMU-366: Potent ...Read More